Iron and insulin resistance

Fargion, Silvia; Dongiovanni, Paola; Guzzo, Adam C.; Colombo, Sara; Valenti, L.; Fracanzani, Anna Ludovica

doi:10.1111/j.1365-2036.2005.02599.x

Cited by 91 publications

(69 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, recent reports showed that iron status influences insulin signaling and glucose uptake in the liver 27 and adipose tissue. 28 Iron overloading decreased insulin signaling evaluated by the phospho-Akt/Akt ratio and up-regulated adipokines favoring insulin resistance such as resistin, 28 which can explain the independent association between ferritin level and insulin resistance in our study.…”

Section: The Association Between Insulin Resistance and Serum Ferritimentioning

confidence: 99%

Serum Ferritin Level is an Independent Predictor of Insulin Resistance in Non-diabetic Men Aged Between 30-69 Years: Korean National Health and Nutrition Examination Survey 2008-2010

Koo

Kim

et al. 2013

J Lipid Atheroscler

View full text Add to dashboard Cite

Section: The Association Between Insulin Resistance and Serum Ferritimentioning

confidence: 99%

Serum Ferritin Level is an Independent Predictor of Insulin Resistance in Non-diabetic Men Aged Between 30-69 Years: Korean National Health and Nutrition Examination Survey 2008-2010

Koo

Kim

et al. 2013

J Lipid Atheroscler

View full text Add to dashboard Cite

“…Facchini et al [110] have shown improvement in liver enzyme levels in 17 NAFLD patients with impaired glucose tolerance undergoing serial phlebotomy. According to Fargion et al [111], in 42 NAFLD patients, serum transaminase levels were significantly decreased after a 4-month hypocaloric diet, and a further reduction was observed after phlebotomies. Sumida et al [112] also reported that phlebotomy decreased serum transaminase activities in Japanese patients with biopsy-proven NASH.…”

Section: Metformin Cq: Are Biguanides Effective For Patients With Nafmentioning

confidence: 99%

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

et al. 2015

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is currently the most common cause of chronic liver disease in industrialized countries worldwide, and has become a serious public health issue not only in Western countries but also in many Asian countries including Japan. Within the wide spectrum of NAFLD, nonalcoholic steatohepatitis (NASH) is a progressive form of disease, which often develops into liver cirrhosis and increases the risk of hepatocellular carcinoma. In turn, a large proportion of NAFLD/NASH is the liver manifestation of metabolic syndrome, suggesting that NAFLD/NASH plays a key role in the pathogenesis of systemic atherosclerotic diseases. Currently, a definite diagnosis of NASH requires liver biopsy, though various noninvasive measures are under development. The mainstays of prevention and treatment of NAFLD/NASH include dietary restriction and exercise; however, pharmacological approaches are often necessary.Currently, vitamin E and thiazolidinedione derivatives are the most evidence-based therapeutic options, although the clinical evidence for long-term efficacy and safety is limited. This practice guideline for NAFLD/NASH, established by the Japanese Society of Gastroenterology in cooperation with The Japan Society of Hepatology, covers lines of clinical evidence reported internationally in the period starting from 1983 to January 2012, and each clinical question was evaluated using the GRADE system. Based on the primary release of the full version in Japanese, this English summary provides the core essentials of this clinical practice guideline comprising the definition, diagnosis, and current therapeutic recommendations for NAFLD/NASH in Japan.

show abstract

“…At present, treatment strategies for NAFLD are involved in prevention by modifying risk-factors of the disease, such as calorie restriction and physical exercise. The in vitro investigation of iron chelators has shown that the addition of chelator improves the insulin resistance of hepatocytes [49]. While the in vitro data look promising, the effect of iron removal on insulin resistance in vivo needs to be validated prospectively in NAFLD patients with documented hepatic iron excess.…”

Section: Non-alcoholic Fatty Liver Disease and Metabolic Syndromementioning

confidence: 99%

Iron chelation beyond transfusion iron overload

Pietrangelo

2007

Am. J. Hematol.

View full text Add to dashboard Cite

The effects of systemic iron overload in hereditary (e.g., classic HFE hemochromatosis) or acquired disorders (e.g., transfusion-dependent iron overload) are well known. Several other iron overload diseases, with an observed mild-to-moderate increase in iron in selected organs (e.g., the liver or the brain), or with ``misdistribution{''} of iron within cells (e.g., reticuloendothelial cells) or subcellular organelles (e.g., mitochondria), have been recognized more recently. The deleterious impact of any excess iron may be high as active redox iron may directly contribute to cell damage or affect signaling pathways involved in cell necrosis-apoptosis or organ fibrosis and cancer. This article discusses the potential use of iron chelation therapy to treat iron overload from causes other than transfusion overload.

show abstract

Iron and insulin resistance

Cited by 91 publications

References 8 publications

Serum Ferritin Level is an Independent Predictor of Insulin Resistance in Non-diabetic Men Aged Between 30-69 Years: Korean National Health and Nutrition Examination Survey 2008-2010

Serum Ferritin Level is an Independent Predictor of Insulin Resistance in Non-diabetic Men Aged Between 30-69 Years: Korean National Health and Nutrition Examination Survey 2008-2010

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

Iron chelation beyond transfusion iron overload

Contact Info

Product

Resources

About